Octapharma Plasma, Inc. Sustainability Profile
Octapharma Plasma, Inc., a leading player in the biopharmaceutical industry, is headquartered in the United States and operates numerous plasma donation centres across the country. Founded in 1983, Octapharma has established itself as a key provider of human protein therapies, focusing on the development and production of high-quality plasma-derived products. The company’s core offerings include immunoglobulins, clotting factors, and albumin, which are essential for treating various medical conditions. Octapharma's commitment to innovation and quality has positioned it as a trusted name in the market, with notable achievements in expanding its operational footprint and enhancing patient care. With a strong emphasis on safety and efficacy, Octapharma Plasma continues to play a vital role in the healthcare landscape, making significant contributions to the treatment of patients worldwide.
DitchCarbon Score
How does Octapharma Plasma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Octapharma Plasma, Inc.'s score of 18 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Octapharma Plasma, Inc.'s reported carbon emissions
Octapharma Plasma, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. As such, there are no recorded emissions figures in kg CO2e, and no climate commitments or pledges have been disclosed. In the absence of specific data, it is important to note that many organisations in the biopharmaceutical sector are increasingly focusing on sustainability and reducing their carbon footprints. This includes setting science-based targets and engaging in initiatives aimed at minimising environmental impact. However, without specific commitments or data from Octapharma Plasma, Inc., it is unclear how they align with these industry trends. Overall, while Octapharma Plasma, Inc. has not provided emissions data or reduction targets, the broader industry context suggests a growing emphasis on climate responsibility and sustainability.
How Carbon Intensive is Octapharma Plasma, Inc.'s Industry?
How Carbon Intensive is Octapharma Plasma, Inc.'s Location?
Octapharma Plasma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Octapharma Plasma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
